Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: Good response with tolerability

Haruhito Azuma, Teruo Inamoto, Kiyoshi Takahara, Naokazu Ibuki, Kohei Koyama, Synya Utimoto, Yutaka Fujisue, Hirohumi Uehara, Kazumasa Komura, Hayahito Nomi, Takanobu Ubai, Yoji Katsuoka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.

Original languageEnglish
Pages (from-to)3737-3746
Number of pages10
JournalAnticancer Research
Volume30
Issue number9
Publication statusPublished - 01-09-2010

Fingerprint

Ethinyl Estradiol
Prostatic Neoplasms
Hormones
Etoposide
Therapeutics
Safety
Clinical Protocols
Disease Progression
Survival Rate
Quality of Life
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Azuma, H., Inamoto, T., Takahara, K., Ibuki, N., Koyama, K., Utimoto, S., ... Katsuoka, Y. (2010). Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: Good response with tolerability. Anticancer Research, 30(9), 3737-3746.
Azuma, Haruhito ; Inamoto, Teruo ; Takahara, Kiyoshi ; Ibuki, Naokazu ; Koyama, Kohei ; Utimoto, Synya ; Fujisue, Yutaka ; Uehara, Hirohumi ; Komura, Kazumasa ; Nomi, Hayahito ; Ubai, Takanobu ; Katsuoka, Yoji. / Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer : Good response with tolerability. In: Anticancer Research. 2010 ; Vol. 30, No. 9. pp. 3737-3746.
@article{23af57ce880c4866bf1b4eb508a0ecb4,
title = "Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: Good response with tolerability",
abstract = "Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70{\%} of patients showed a >50{\%} reduction (complete response [CR] 51{\%}, partial response 23{\%}) and >90{\%} showed a clinical response. Of 58 patients with measurable lesions, 24{\%} (14/58) showed a CR, and most of these patients (13/14, 93{\%}) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.",
author = "Haruhito Azuma and Teruo Inamoto and Kiyoshi Takahara and Naokazu Ibuki and Kohei Koyama and Synya Utimoto and Yutaka Fujisue and Hirohumi Uehara and Kazumasa Komura and Hayahito Nomi and Takanobu Ubai and Yoji Katsuoka",
year = "2010",
month = "9",
day = "1",
language = "English",
volume = "30",
pages = "3737--3746",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

Azuma, H, Inamoto, T, Takahara, K, Ibuki, N, Koyama, K, Utimoto, S, Fujisue, Y, Uehara, H, Komura, K, Nomi, H, Ubai, T & Katsuoka, Y 2010, 'Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: Good response with tolerability', Anticancer Research, vol. 30, no. 9, pp. 3737-3746.

Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer : Good response with tolerability. / Azuma, Haruhito; Inamoto, Teruo; Takahara, Kiyoshi; Ibuki, Naokazu; Koyama, Kohei; Utimoto, Synya; Fujisue, Yutaka; Uehara, Hirohumi; Komura, Kazumasa; Nomi, Hayahito; Ubai, Takanobu; Katsuoka, Yoji.

In: Anticancer Research, Vol. 30, No. 9, 01.09.2010, p. 3737-3746.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer

T2 - Good response with tolerability

AU - Azuma, Haruhito

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Ibuki, Naokazu

AU - Koyama, Kohei

AU - Utimoto, Synya

AU - Fujisue, Yutaka

AU - Uehara, Hirohumi

AU - Komura, Kazumasa

AU - Nomi, Hayahito

AU - Ubai, Takanobu

AU - Katsuoka, Yoji

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.

AB - Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.

UR - http://www.scopus.com/inward/record.url?scp=77958558517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958558517&partnerID=8YFLogxK

M3 - Article

C2 - 20944163

AN - SCOPUS:77958558517

VL - 30

SP - 3737

EP - 3746

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -